Faeth Therapeutics, Inc. (FTH): Total Liabilities
$4.31M
As of 2025-12-31
$9.58M
As of 2026-06-30
-34.0%
3-year compound annual growth
-4.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.31M | -38.2% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $6.97M | -26.4% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $9.48M | -36.7% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $14.97M | +123.0% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $6.71M | +21.3% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $5.54M | n/a | 2022-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | 2025-12-31 | $4.31M | -38.2% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.66M | +20.0% |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $4.25M | -11.1% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $7.12M | +24.5% |
| Immunic, Inc. (IMUX) | 2025-12-31 | $30.73M | +36.9% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $7.24M | -7.2% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $8.13M | -24.2% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $1.34M | +32.0% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
Compare FTH, CRVO, GANX, MBRX side by side · Screen every company in Pharmaceutical Preparations ↗